Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment of HER2 Amplified Advanced Gastric, Gastroesophageal Junction and Esophageal Cancer

NCT02274012 is registered in ClinicalTrials.gov with Columbia University as lead sponsor.

NCT NCT02274012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02274012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment of HER2 Amplified Advanced Gastric, Gastroesophageal Junction and Esophageal Cancer
Lead sponsor
Columbia University
Phase
Phase 2
Overall status
Withdrawn
Start date
May 29, 2014
Completion date
August 12, 2015
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer, gastrooesophageal cancer, her-2 positive gastric cancer